In contrast, 35% of juvenile DM (JDM) patients have anti-TIF1γ antibodies by a review article depending on several large registries developed in the USA, Canada and the UK [10], while 17.4% and 22% of JDM patients do in a report of 58 cases from Turkey and another report of 64 cases from Argentina [11,12]. Here, TRIM33 is linked to dermatomyositis.